Optimal approach to potentially resectable liver metastases from colorectal cancer

被引:4
作者
Falcone, Alfredo [1 ,2 ]
Fornaro, Lorenzo [1 ]
Loupakis, Fotios [1 ]
Masi, Gianluca [1 ]
Vasile, Enrico [1 ]
机构
[1] Ist Toscano Tumori, Dept Oncol, Azienda Livorno USL6, Livorno, Italy
[2] Univ Pisa, Dept Oncol Transplants & New Technol Med, I-56100 Pisa, Italy
关键词
D O I
10.1586/14737140.8.10.1533
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1533 / 1539
页数:7
相关论文
共 51 条
[1]  
Adam R, 2001, ANN SURG ONCOL, V8, P347
[2]  
[Anonymous], J CLIN ONCOL S
[3]   KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
De Braud, F. G. ;
Volovat, C. ;
Nippgen, J. ;
Stroh, C. ;
Celik, I. ;
Koralewski, P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4]  
BOKEMEYER C, 2007, J CLIN ONCOL, V25
[5]   Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966 [J].
Cassidy, J. ;
Cunningham, D. ;
Berry, S. R. ;
Rivera, F. ;
Clarke, S. J. ;
Kretzschmar, A. ;
Diaz-Rubio, E. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[6]   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[7]   Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A Multicenter study of the Gruppo Oncologico Dell'Italia Meridionale [J].
Colucci, G ;
Gebbia, V ;
Paoletti, G ;
Giuliani, F ;
Caruso, M ;
Gebbia, N ;
Carteni, G ;
Agostara, B ;
Pezzella, G ;
Manzione, L ;
Borsellino, N ;
Misino, A ;
Romito, S ;
Durini, E ;
Cordio, S ;
Di Seri, M ;
Lopez, M ;
Maiello, E .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4866-4875
[8]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[9]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[10]   KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].
De Roock, W. ;
Piessevaux, H. ;
De Schutter, J. ;
Janssens, M. ;
De Hertogh, G. ;
Personeni, N. ;
Biesmans, B. ;
Van Laethem, J. -L. ;
Peeters, M. ;
Humblet, Y. ;
Van Cutsem, E. ;
Tejpar, S. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515